Compare · GLP-1 agonist
Orforglipron vs Semaglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Orforglipron | Semaglutide | |
|---|---|---|
| Evidence | Strong human | Strong human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An oral, non-peptide (small-molecule) GLP-1 receptor agonist, FDA-approved in April 2026 as Foundayo for chronic weight management. It is a once-daily pill with no food or timing restrictions — not a peptide, and not an injectable. | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. |
| Full profile → | Full profile → |
Orforglipron
Orforglipron (brand name Foundayo) is a GLP-1 receptor agonist — the same drug class as semaglutide and tirzepatide — but with one defining difference: it is a small molecule, not a peptide, and it is taken as a once-daily pill rather than an injection. In April 2026 the FDA approved it for chronic…
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most compounds we profile, the human evidence here is large, long, and consistent — so the honest job is to describe where it holds up and where it does not.